.Nature Medicine, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) procedure of clients along with HER2+ sophisticated breast cancer cells and energetic or even dependable brain metastases presented constant intracranial activity and also wide spread efficiency of T-DXd.